Send to

Choose Destination
J Cardiovasc Thorac Res. 2014;6(3):191-5. doi: 10.15171/jcvtr.2014.010. Epub 2014 Sep 30.

Mitral valve restenosis after percutaneous transmitral valvuloplasty, role of continuous inflammation.

Author information

Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
School of Management and Information, Shiraz University of Medical Sciences, Shiraz, Iran.



High sensitive C-Reactive Protein (hs-CRP) is increased in acute and chronic rheumatic fever (RF), but is unknown whether serum levels of hs-CRP is correlated with late restenosis of mitral valve (MV) after Percutaneous transvenous mitral commissurotomy (PTMC). The aim of this study is to determine relationship between hs-CRP and MV restenosis 48-36 months after performing PTMC.


A total of 50 patients who had undergone PTMC due to rheumatic etiology (41 female, 9 male; mean age 46 ± 11, range 27-71), all followed up on an out patients basis 36 months after PTMC, were included in the study. The hs-CRP was measured using an enzyme-linked immunosorbent assay (ELISA) kits.


No association was found between hs-CRP level and mean transmitral valve gradient 36 months after PTMC, MV area by planimetry, pulmonary artery systolic pressure, mitral regurgitation grade, left atrial diameter, atrial fibrillation (AF) rhythm and Wilkins score.


Our study have shown that there is no association between hs-CRP and MV restenosis in patients with rheumatic heart disease (RHD) who underwent PTMC. Therefore, it has been postulated that inflammation is not a cause of post PTMC restenosis.


C-Reactive Protein (CRP); Inflammation; PTMC

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center